Premium
Molecularly targeted therapies for nonmelanoma skin cancers
Author(s) -
Liu Lucinda S.,
Colegio Oscar R.
Publication year - 2013
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.12017
Subject(s) - vismodegib , dermatofibrosarcoma protuberans , medicine , cetuximab , basal cell carcinoma , skin cancer , basal cell , cancer research , imatinib , sarcoma , dermatology , cancer , pathology , colorectal cancer , myeloid leukemia
Over the past two decades, advances in the fields of cancer genetics and molecular biology have elucidated molecular pathways that cause numerous cutaneous malignancies. This in turn has spurred the rational design of molecularly targeted therapies. In this review, we discuss the molecular pathways critical to the development of nonmelanoma skin cancers and the novel pharmacologic agents that target them. Included is a review of vismodegib for basal cell carcinoma, cetuximab for squamous cell carcinomas, imatinib for dermatofibrosarcoma protuberans, and sirolimus for Kaposi's sarcoma.